Article
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial.
Lancet (London, England) - 4 Mar 2023
de Langen Adrianus Johannes, Johnson Melissa L, Mazieres Julien, Dingemans Anne-Marie C, Mountzios Giannis, Pless Miklos, Wolf Jürgen, Schuler Martin, Lena Hervé, Skoulidis Ferdinandos, Yoneshima Yasuto, Kim Sang-We, Linardou Helena, Novello Silvia, van der Wekken Anthonie J, Chen Yuanbin, Peters Solange, Felip Enriqueta, Solomon Benjamin J, Ramalingam Suresh S, Dooms Christophe, Lindsay Colin R, Ferreira Carlos Gil, Blais Normand, Obiozor Cynthia C, Wang Yang, Mehta Bhakti, Varrieur Tracy, Ngarmchamnanrith Gataree, Stollenwerk Björn, Waterhouse David, Paz-Ares Luis
Abstract excerpt
BACKGROUND: Sotorasib is a specific, irreversible inhibitor of the GTPase protein, KRASG12C. We compared the efficacy and safety of sotorasib with a standard-of-care treatment in patients with non-small-cell lung cancer (NSCLC) with the KRASG12C mutation who had been previously treated with other anticancer drugs. METHODS: We conducted a randomised, open-label phase 3 trial at 148 centres in 22 countries. We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.